InvestorsObserver
×
News Home

Where Will Rain Oncology Inc (RAIN) Stock Go Next After It Is Higher By 4.35% in a Week?

Thursday, December 14, 2023 09:59 AM | InvestorsObserver Analysts

Mentioned in this article

Where Will Rain Oncology Inc (RAIN) Stock Go Next After It Is Higher By 4.35% in a Week?

Rain Oncology Inc (RAIN) stock is up 4.35% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Rain Oncology Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on RAIN!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With RAIN Stock Today?

Rain Oncology Inc (RAIN) stock is trading at $1.20 as of 9:54 AM on Thursday, Dec 14, a gain of $0.02, or 1.69% from the previous closing price of $1.18. Volume today is elevated. So far 347,283 shares have traded compared to average volume of 114,170 shares. The stock has traded between $1.19 and $1.21 so far today. To screen for more stocks like Rain Oncology Inc click here.

More About Rain Oncology Inc

Rain Therapeutics Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. Click Here to get the full Stock Report for Rain Oncology Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App